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Quantitation of Human Immunodeficiency Virus Provirus and Circulating Virus:
Relationship with Immunologic Parameters
s. Yerly, E. Chamot, B. Hirschel, and L. H. Perrin Central Laboratory of Virology. Division of Infectious Diseases. and
Medical Outpatient Clinic. Geneva University Hospital. Switzerland
Virologic and seroimmunologic parameters were determined in 56 persons infected with hu-
man immunodeficiency virus (HIV). The provirus level varied from 10 to 100,000/106 CD4+
lymphocytes, and genomic HIV RNA was detectable in 39 of 56 patients at a relative concentra-
tion varying from 10 to >250 copies/ml, of serum. Provirus expressed as copies per 106 CD4+
lymphocytes and as circulating virus per milliliter of serum increased with disease progression
and decrease of CD4+ cell concentration. The mean provirus concentration expressed per milli-
liter of blood varied little among categories of patients with various levelsofCD4+ cells, but there
was a progressive increase of circulating HIV genomic RNA. These virologic data suggest that
during the course of HIV infection, an increasing proportion of the remaining CD4+ lympho-
cytes harbor the HIV genome and produce infectious virus. Finally, there was a marked correla-
tion between increased provirus and genomic RNA concentration and three seroimmunologic
markers: decrease in CD4+cell count, p24 antigenemia, and disappearance of antibodies to HIV
core antigen.
Human immunodeficiency virus (HIV) induces a persis-
tent infection that progresses slowly from asymptomatic in-
fection to AIDS. Antiretroviral therapy may delay progres-
sion. The identification of factors that correlate with
progression or regression of HIV infection is important for
prognosis and for the monitoring of treatment.
CD4+ lymphocytes are the main target of HIV infection
[I], and the decline in CD4+ cell concentration is the best
predictive factor for progression to AIDS. Other markers
with predictive value are p24 antigenemia, antibodies to HIV
core antigen (anti-core), and serum levels of neopterin and
.B2-microglobulin [2, 3]. Previous studies [4-6] have at-
tempted to detect HIV itself in plasma and in peripheral
blood mononuclear cells (PBMC) and demonstrated, using
appropriate coculture techniques, that viremia is present in
most infected patients and that the virus load increases with
disease progression. In clinical trials, the biologic effects of
antiviral therapy are assessed mainly by counting CD4+ lym-
phocytes and by measuring .B2-microglobulin and p24 anti-
genemia [7-9]. Quantitative determination of infectious
HIV in PBMC and plasma is expensive and technically de-
manding; it has therefore been done in only a few investiga-
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tions, in which viremia usually decreased after zidovudine
therapy [4, 5].
The polymerase chain reaction (PCR) offers a simple
method to quantify proviral HIV DNA and genomic HIV
RNA. The aim of this study was to determine virologic pa-
rameters in a large group of patients with various clinical
presentations and to analyze the relationship between virolo-
gic parameters, such as provirus and circulating virus, and
seroimmunologic parameters.
Patients and Methods
Study population. Fifty men and 6 women with serum anti-
bodies to HIV-I participated. Eleven were asymptomatic
(Centers for Disease Control [CDC] stage II); 21 had persistent
generalized lymphadenopathy (CDC stage III); 12 had CDC
stage IV disease (10, IV-C-2; 2, IV-D, analyzed together); and
12 had CDC stage IV-C-I disease [10]. The mean CD4+ lym-
phocyte counts in these four subgroups were 497, 481,254, and
45/#LL, respectively. Negative control samples were collected
from 20 blood donors with no antibodies to HIV-I. A number of
participants were on zidovudine treatment: 2 with CDC stage II
disease (55 and 33 days), I with stage III (165 days), 3 with stage
IV-C-2 or IV-D (48,65, and 766 days), and 7 with stage IV-C-l
(83, 120, 139,308,386,572, and 659 days).
Seroimmunologic data. EDTA-treated blood (10-20 mL)
and native blood (10 mL) were collected from the participants
by venipuncture and processed within 4 h. Native blood samples
were centrifuged at 1500 g for 10 min, and sera were aliquoted
and frozen at -70°C. Complete blood count was done, and the
absolute concentrations of CD3, CD4, and CD8 lymphocytes
were determined by flow cytometry (Coulter EPICS IV; Instru-
mente Gesellschaft, Basel, Switzerland) using fluoresceinated
OKT3, OKT4a, and OKT8 monoclonal antibodies (Ortho-
mune; Ortho Diagnostics, Raritan, NJ). HIV-I-specific antibod-
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ies were determined by EIAs (Abbott recombinant HIV-I/HIV-
2 EIA and Envacor, Abbott Laboratories, Abbott Park, IL) and
Western blot (Du Pont, Geneva). Levels of p24 antigen were
measured in duplicate, and positive samples were neutralized
with antibodies to HIV-I (HIVAG-I ; Abbott). Serum f12-mi-
croglobulin levels were determined using a commercial assay
(IMX f1rMicroglobulin; Abbott). All the EIAs were done in
batch testing.
Semiquantitation of HIV provirus. PBMC were isolated by
Ficoll-Paque (Pharmacia, Dubendorf, Switzerland). The pellet
containing 1-20 X 106 PBMC was incubated overnight at 37°C
in a lysis buffer containing 100 mM NaCl, 50 mM TRIS-HCI
(pH 7.5), I mM EDTA, 0.5% SDS, and 100 ILg/mL proteinase
K. After phenol-chloroform extraction, DNA was precipitated
with ethanol and resuspended in TE buffer (10 mM TRIS-HCl,
pH 7.5, I mM EDTA). The LAV-8E5 cell line (National Insti-
tute ofAllergy and Infectious Diseases, AIDS Research and Ref-
erence Reagent Program, Bethesda, MD) containing one copy
of HIV -I provirus per cell was grown in culture as recom-
mended [II]. DNA was extracted from a pellet of 50 X 106 cells
and serially diluted in HIV-negative human genomic DNA to
obtain the equivalent of 1-1000 LAV-8E5 cells in I ILg of hu-
man genomic DNA/ I0 ILL. For provirus amplification, a 238-bp
segment of a conserved region of the HIV-I pol gene was se-
lected and amplified [12]. All samples were tested in duplicate
using I ILg ofgenomic DNA corresponding to 150,000 cells/test.
The reaction mixture of 100 ILl containing I ILg of genomic
DNA and 2.5 units of DNA polymerase (Amplitaq; Perkin-
Elmer Cetus, Norwalk, CT) was adjusted to 10 mM TRIS-HCl
(pH 8.3),50 mMKCl, 2.5 mM MgCI2, 0.5 mM ofeach deoxynu-
cleoside triphosphate (dNTP), 0.5 ILM of POL I and POL 2
primers (POL 1,5'-TGGGTACCAGCACACAAAGG, 3734-
3753 in HIV BRU; POL 2,5'-ACTTGTCCATGCATGGC-
TTC, 3953-3972 in HIV BRU) [13]. The reaction was cycled
37 times (94°C, I min; 56°C, 1.5 min; 72°C, I min) using a
DNA thermal cycler (model 480; Perkin-Elmer Cetus) [12].
Five samples of human genomic DNA containing 1,3, 10, 100,
and 1000 copies of HI V provirus from the LAV-8E5 cells were
included in each experiment.
The denatured PCR product was applied to nylon membrane
(GeneScreenPlus; NEN, Boston) using a vacuum filtration appa-
ratus (Minifold II; Schleicher & Schuell, Keene, NH). Filters
were incubated for I h at 45°C in prehybridization solution (4X
SSC [standard sodium citrate], 5X Denhardt's solution, 5%SDS,
20 mM sodium phosphate [pH 7], 100 ILg/mLsheared and dena-
tured salmon sperm DNA) and hybridized to a 32P-Iabeled
probe (5'-AATTGGAGAGCAATGGCTAGTGA, 3863-3885
in HIV BRU) by incubation at 50°C overnight (specific activity,
108 cpm/ILg). Then filters were washed 15 min at 50°C, once
with 3X SSC and 0.1 %SDS, once with 0.5X SSC and 0.1 %SDS,
then twice with 0.1 X SSC and 0.1 % SDS. The radioactivity of
each spot applied to the nylon membrane was determined using
the Phosphorlmager system (Molecular Dynamics, Basel, Swit-
zerland).
The number of HI V proviral copies was calculated in relation
to the standard curve generated by using DNA from defined cell
equivalent of the LAV-8E5 cell line. To relate the number of
proviral copies to 106 CD4 cells, the number ofcopies measured
in I ILg of DNA corresponding to 150,000 cells was multiplied
by a correcting factor (6.66) and further divided by the ratio of
CD4 cells per microliter to total lymphocytes per microliter. We
have shown previously that the sensitivity ofproviral HIV DNA
detection is on the order of one proviral copy per sample [12,
13]. The one-copy samples were detected in 6 of 14 experiments
and three copies in at least one of the two duplicate amplifica-
tions in all assay runs. Negative samples (serum from Hl'V-ser-
onegative blood donors included in each run) gave numbers
(pixels) nearly the same as the background value measured on
the membrane in the absence of DNA. Reference samples with
the equivalent of one proviral copy gave numbers at least twice
the background value. The coefficient of correlation between
points of the standard curve is typically --0.98. Interassay varia-
tion, checked using 10 different samples in three different exper-
iments, was 30%; intraassay variation was 19%.
HIV RNA semiquantitation. Circulating genomic HIV RNA
was detected after immunocapture of the virus, reverse tran-
scription (RT), and cDNA amplification. To prepare the im-
munoabsorbent, IgG was purified from 35 mL of pooled sera
from 10 patients with a high titer of anti-HIV-I antibodies and
no circulating antigen by ammonium sulfate precipitation [14]
and diethylaminoethyl cellulose chromatography. IgG (200 mg)
was coupled to 5 g of cyanogen bromide-activated Sepharose
4B (Pharmacia) according to the manufacturer's recommenda-
tions. The final step was extensive washing with 2 L of2% Noni-
det P-40 (NP40) in TE buffer. The coupling efficacy was 75%.
Sepharose was stored in PBS plus 0.02% NaN3 at 4°C.
Immunocapture of circulating virus was achieved as follows:
100 ILL of frozen serum or dilutions was adjusted to 200 ILL with
150 mM NaCI and incubated on a rotator overnight at 4°C with
20 ILL of 5% Sepharose suspension (a threefold excess as deter-
mined in preliminary experiments). The Sepharose particles
were pelleted, washed twice with 150 mM NaCl, suspended in 5
ILL of 1%NP40, and heated at 95°C for 5 min. RT was done in
20 ILL containing 50 mM TRIS-HCI (pH 8.3), 20 mM KCI, 6
mM MgCI2, I mM of each dNTP, 25 units of RNase inhibitor
(Boehringer, Mannheim, Germany), 100 pmol of dN 6 random
primers (Boehringer), and 200 units of Moloney murine leuke-
mia virus reverse transcriptase (BRL, Bethesda, MD). The mix-
ture was incubated 10 min at room temperature and I h at
42°C, heated to 95°C for 15 min, then 2 ILl of 0.05 mg/mL
solution of proteinase K (Sigma, St. Louis) was added. The mix-
ture was incubated at 55°C for 30 min, heated to 95°C for 15
min, and cooled to 4°C. Next, cDNA was amplified as described
above for provirus amplification.
Circulating genomic HIV RNA was measured semiquantita-
tively by using serial dilutions of serum in the absorption step.
All sera were tested at least twice without dilution (100 ILL of
serum) and when diluted 10 and 25 times with 150 mM NaCl.
Samples positive without dilution were diluted twice and tested
singly. Identical results were obtained with duplicate tests for all
but 3 samples; these 3 were retested three times, and the result
used was the mean of the five determinations. Each set ofexperi-
ments included a negative control (serum from a blood donor),
two known weakly reactive sera, and, for the PCR step, dilutions
of LAV-8E5 DNA. The two weakly positive samples (RNA of
< 10 but> I copy /rnl.) included in each run gave positive results
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Figure 1. HIV provirus levels in relation to
circulating genomic RNA. Provirus is ex-
pressed as log of provirus/LO" CD4+ lympho-
cytes. Participants are divided into fourgroups
on basis of levelof RNA moleculesdetected/
mL of serum. Number of participants with
various levels of provirus for each category is
shown at bottom.
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in 14 of 15 experiments. The results of RNA copy number are
measured as a function of the dilutions of LAV-8E5 DNA and
are expressed as undetectable, > 10 copies/ml. (positive signal
using 100 JLL of serum and negative signal using 10 JLL of
serum), > 100 copies/ml., and >250 copies/ml., As a control,
serum of each participant was absorbed on Sepharose, and the
pellet was amplified without the reverse transcriptase step; none
gave a positive signal. For determining circulating HIV RNA,
-70°C frozen stored sera were tested within 3 months ofcollec-
tion. No decline of HIV RNA level has been observed when
serial unthawed samples have been tested repeatedly over 4-6
months.
Statistical analysis. Groups were compared using the x2test
with Yates's correction or the two-tailed Fisher's exact test.
Results
Figure I presents the relationship between number ofpro-
viral copies and concentration of genomic viral RNA in
serum. The provirus was detectable in all participants,
whereas genomic RNA was detectable in 39 (70%) of 56. In
general, persons with a high number of proviral copies also
had high RNA levels. High numbers of proviral copies
(~ 1000 copies/I 06 CD4+ lymphocytes) were detected in all
participants with > 100 copies of genomic RNA/mL of
serum compared with 22 (52%) of42 participants with < 100
copies/ml. (P = .008).
In figure 2, provirus and circulating virus are shown in
relation to clinical stages. A high number of proviral copies
(log ~3) was found in 20 (83%) of 24 participants in CDC
stages IV-C-2, IV-C-l, or IV-D compared with 16 (50%) of
32 participants in CDC stages II and III (P = .02). More than
100 RNA copies/mi. were found in 11 (46%) of 24 partici-
pants with stage IV disease compared with 3 (9%)of32 partic-
ipants with stage II or III (P = .005).
The concentration ofCD4+ lymphocytes in the peripheral
blood is often used as a prognostic marker. In figure 3, results
are expressed in relation to four categories ofCD4+ cell con':'
centration. Concentrations of provirus per 106 CD4+ lym-
phocytes and of circulating genomic RNA both increase
when the CD4+ cell count decreases. More than 1000 pro-
viral copies were found in 25 (96%) of 26 participants with
CD4+ cell counts <200!JLL compared with 11 (37%) of 30
participants with CD4+ cell counts >200/Jl,L (P < .001).
More than 100 RNA copies/ml, were found in 13 (50%) of
26 participants with CD4+ cell counts <200/JLL compared
with 1 (3%) of 30 participants with CD4+ cell counts >200/
JLL (P < .001).
Figure 4 shows concentrations (values) ofprovirus (DNA)
and circulating genomic RNA and the ratio between them
for individual subjects. The values are expressed per milli-
liter of blood, to determine the virus load, and are presented
for four categories of CD4+ concentration. It appears that
individual values of provirus vary to a greater extent within
each category than do the mean values of the four categories.
Furthermore, this does not seem to be linked to zidovudine
treatment. In contrast, the percentage of patients with circu-
lating genomic HIV RNA increases markedly in the two
groups ofparticipants with CD4+ cell counts < 200/Jl,L com-
pared with those with>200/JLL.
The ratio of provirus to circulating genomic RNA (also
shown in figure 4) indicates that the concentration of pro-
virus exceeds the concentration of circulating virus until late
in the disease (participants with CD4+ cell counts <50/JLL).
In figures 5-7, concentrations of provirus and circulating
genomic RNA are reported in relation to presence or ab-
sence of p24 antigen, to high or medium level of or absence
of anti-p24 antibodies, and to ~3 or <3 mg/mL {j2-micro-
globulin. Associations were found between virologic parame-
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Log proviral DNA/10 ISCD4 (50%) of 18 participants without anti-p24 antibodies com-
pared with 5 (13%) of 38 participants with anti-p24 antibod-
ies (P = .007). However, the associations were far from per-
fect; for example, 50% of p24 antigen-negative subjects had
detectable circulating genomic RNA, and some participants
with high levels of anti-core antibodies had high levels of
provirus and circulating RNA.
Only limited follow-up was available after these tests (be-
tween September 1990 and May 1991). Five subjects have
died (21 days, 91 days, 105 days, 7 months, and 8 months)
since completion of this investigation. All had >250 copiesj
mL circulating genomic RNA (of9 total subjects with >250
copiesjmL) and> 104 copies of provirusj I 06 CD4+ cells (of
18 total subjects with that level). Their CD4+ cell counts at
the time of the investigation were 2,7,8, 16, and 7 I jilL.
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Figure 3. HIV load in relation to CD4+ lyrnphocytes/ul., Partici-
pants are divided into four groups according to concentration of
CD4+ in peripheral blood. Number ofCD4+ cells in each category
is shown at bases of columns. Results of provirus and circulating
HIV RNA are expressedas in figure 2.
Figure 2. HIV load in relation to disease stage according to
Centers for DiseaseControl (CDC) classification. Top, number of
proviral copies in different CDC stages.Results of provirus (DNA)
are expressed as log of provirus per 106 CD4+ lymphocytes. Bot-
tom, number of RNA rnolecules/ml. of serum for different CDC
stages. Results of circulating genomic HIV RNA are reported as
undetectable, > 10 molecules/rnl., > 100 molecules/rnl., and>250
molecules/ml., Number of participants is shown at bottom of each
graph.
ters and both p24 antigen and anti-p24 antibodies but not
{32-microglobulin. As shown in figure 5, > 1000 copies of
HIV provirus/TO" CD4+ lymphocytes were detected in 20
(91 %)of 22 participants with p24 antigen compared with 16
(47%) of 34 participants without p24 antigen (P = .002).
More than 100 RNA copiesjmL were found in II (50%) of
22 participants with p24 antigen compared with 3 (9%) of 34
participants without p24 antigen (P = .002). As shown in
figure 6, > 1000 copies of provirus were found in 17 (94%) of
18 participants without anti-p24 antibodies compared with
19 (50%) of 38 participants with anti-p24 antibodies (P =
.006). More than 100 RNA copiesjmL were found in 9
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Discussion
In this study, a close association was observed between
virologic parameters and seroimmunologic markers com-
monly used for the evaluation of HIV infection, such as
CD4+ lymphocytes, p24 antigenemia, and anti-core anti-
bodies.
The virologic parameters selected explore different
aspects. Semiquantitation of the provirus is related to the
reservoir of HIV, although cell types not represented in the
peripheral blood (such as Langerhans cells) may be an im-
portant reservoir of HIV [15]. Circulating genomic RNA re-
flects viremia and is linked not only to viral replication but
also to viral clearance, which may be more efficient in early
stages ofHIV infection. The result ofthese two factors (repli-
cation and clearance of HIV) as determined by circulating
genomic RNA is a sensitive index of the quantity of HIV
available for propagation of the infection.
The virologic parameters measured in this investigation
provided semiquantitative information. The choice of a pol
gene segment for HIV DNA amplification was based on the
low number ofbase substitution among HIV isolates in these
parts of the pol gene [12, 13]. A method based on immuno-
capture of the virus rather than RNA purification was se-
lected for the detection ofcirculating HIV. For the capture of
circulating virus, we used polyclonal (rather than monoclo-
nal) antibodies to HIV to avoid biases linked to sequence
variations ofgp 120 among HIV isolates. The absorption step
is convenient in terms of rapidity, simplicity, specificity
(only the virus is absorbed), and suitability for quantitation
by limiting dilutions. The main limitation ofthe quantitation
of RNA is linked to the RT step, whose efficacy is --5% [16]
(in contrast, DNA amplification can detect a single copy of
provirus [12, 17, 18]). For this reason, it may be more appro-
priate to express the results of circulating RNA in arbitrary
units rather than in number of RNA molecules per milliliter.
However, for simplicity of expression and to avoid artificial
manipulations of the data, results are expressed in terms of
relative concentration of RNA molecules per milliliter. Al-
though they are relative, RNA results are reproducible; they
are therefore suitable for comparative studies.
When the provirus measurements were regarded in rela-
tion to 106 CD4+ lymphocytes, we observed, as have others,
an increase of proviral copies with progression of HIV infec-
tion and with the decrease in CD4+ cell concentration [3, 4,
17,19-21]. Only a few copies of provirus are detectable in
each infected PBMC [17], so our results suggest there is a
progressive increase in the percentage of cells carrying the
provirus that may reach 10%. The other mode of expressing
the number of proviral copies per milliliter of blood reflects
the absolute concentration of the provirus and is a better
estimate of the HIV reservoir in CD4+ lymphocytes. During
the progression of HIV infection, the mean concentration of
provirus per milliliter of blood increases by only a factor of
three for subjects with the lowest concentrations of CD4+
lymphocytes. Greater variations are observed among individ-
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tion system [3,4,6, 19,22]. For example, in one large study,
the percentage of plasma coculture positivity varied from
23% in asymptomatic participants to 82% in patients with
AIDS [3]. The marked variation in concentration of in-
fectious virus reported by different groups using HIV culture
[3, 4, 19] underlines the need of alternative approaches for
the analysis of virologic parameters. Recently, Zang et al.
[16], using an RNA PCR assay, detected circulating genomic
RNA in 100%ofindividuals with AIDS-related complex and
in 60%ofasymptomatic individuals. Other investigators have
reported a correlation between disease stage and viral RNA
in serum [22, 23], as was seen in the present study.
Participants with CD4+ counts >200//-LL can be divided
into two subgroups: those without detectable circulating
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Figure 5. HIV load in relation to p24 antigenemia (p24 Ag).
Participantsare divided into those without and those with p24 Ag.
Results of provirusand circulating HIV RNA are expressedas in
figure 2.
uals, and these are relatively independent of their CD4+ cell
counts. All together, these data suggest that in peripheral
blood the increase in percentage ofcells carrying the provirus
is counterbalanced by a decrease in the concentration ofcells
susceptible to HIV infection during the progression of HIV
infection. In addition, in the present investigation, values
determined in participants on zidovudine (most of them on
long-term zidovudine, mean duration of 261 days) did not
differ significantly from those not on zidovudine.
Circulating genomic RNA was detected in 70%of the par-
ticipants. The proportion of subjects with detectable geno-
mic RNA and the amount of genomic RNA increased with
progression of HIV infection. These results are compatible
with those of earlier investigations using a coculture detec-
HIV RNA in serum
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Figure 6. HIV load in relation to antibodies to HIV coreantigen
(anti-core). Participants are divided into those without detectable
anti-coreantibodies(undetected)and those with low(index, 1-10)
and high levels of anti-core antibodies (index, ;;;:'10). Results of
provirusand circulatingHIV RNA are expressed as in figure 2.
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association is observed with anti-core antibodies. The detec-
tion ofgenomic HIV RNA in participants with high levels of
anti-core antibodies is not surprising, since immunocapture
is designed to capture intact virus whose surface component
is gp 160 and its process products. The absence ofassociation
with ~2-microglobulin, whose increase has been shown to
correlate with progression ofAIDS [24, 25], may be due to a
preferential link of ~2-microglobulinincrease with cell acti-
vation rather than with HIV multiplication itself. In this con-
text, ~2-microglobulin levels may be more influenced by op-
portunistic infections than by HIV load.
In conclusion, the present investigation demonstrated a
closed association of virologic parameters with CD4+ con-
centration, p24 antigen, and anti-core antibodies. It also
shows that a high proportion of participants with CD4+ cell
counts >200/JLL already have high levels of provirus and
circulating genomic RNA; these individuals may benefit
most from early antiviral therapy. Finally, the technique of
semiquantitation of circulating genomic HIV RNA is spe-
cific and relatively simple and should be ofvalue in monitor-
ing the effect of antiviral drugs.
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RNA (14 participants) and those with RNA [16]. It is tempt-
ing to speculate that the patients with circulating RNA are at
higher risk for rapid progression of HIV infection and that
they would benefit most from antiviral treatment. Verifica-
tion of this hypothesis will require long prospective studies.
Ours was a cross-sectional study with only 9 months of fol-
low-up. During this period, 5 subjects with >250 circulating
RNA molecules/ml, died, emphasizing the negative prog-
nostic value of high levels of circulating genomic RNA.
A positive association between circulating genomic HIV
RNA and p24 antigenemia was observed; this indirectly vali-
dates the techniques used for RNA determination. All p24
antigen-positive but only 50% of p24 antigen-negative sub-
jects were found to be RNA-positive. As expected, an inverse
60..
Figure 7. HIV load in relation to .B2-microglobulin. Participants
are groupedaccording to levelof .B2-microglobulin; limit of 3 rng/L
was arbitrarily selectedand corresponds to 250% of mean value of
healthy adults. Results of provirus and circulating HIV RNA are
expressed as in figure 2.
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